

## 新たなデータは若年乳がん患者における術後補助療法のガイドとなる(Abstract 503)

**TAILORx: 閉経前女性の乳がん再発予防目的の術後補助療法に関する新たな情報**

TAILORx: New information about adjuvant therapy to prevent recurrence of breast cancer in premenopausal women

若年女性の乳がん再発リスクを、典型的な臨床像(腫瘍サイズおよび組織学的グレード分類)に基づき評価することにより、21-遺伝子アッセイによる再発スコア(RS)に補完的な予後情報が追加される。と2019 ASCO Annual Meeting で発表され、*New England Journal of Medicine* に掲載された。TAILORx試験の研究者らは、RSの結果が16~20で50歳以下の女性は臨床的にリスクが低く化学療法の必要性がない、と述べている。このことはまた、より効果的な抗エストロゲン療法でベネフィットを得られる若年女性を同定するのにも役立つ可能性がある。

### Full Text

New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years of age or younger, or premenopausal, emerged from the landmark Trial Assigning Individualized Options for Treatment (Rx), or TAILORx. An analysis of a pre-specified secondary endpoint in this largest-ever breast cancer treatment trial found that an assessment of a woman's recurrence risk based on classic clinical features (tumor size and histologic grade) adds prognostic information that is complementary to the 21-gene Recurrence Score (RS) test. Integration of the RS with clinical risk may help identify more young women who may be spared chemotherapy than originally reported. It may also help identify young women who stand to benefit from more effective anti-estrogen therapy. The analysis was published in the *New England Journal of Medicine* and presented at the 2019 meeting of the American Society of Clinical Oncology.

The new findings complement the original, definitive TAILORx conclusion reported last year, that 70 percent of women with the most common type of breast cancer; that is, hormone receptor (HR)-positive, HER2-negative, axillary lymph node-negative breast cancer, can forego chemotherapy when guided by the RS. The trial was supported by the National Cancer Institute, part of the National Institutes of Health, and designed and led by the ECOG-ACRIN Cancer Research Group.

"Last year's TAILORx results gave clinicians high-quality data to inform personalized treatment recommendations for women," said lead author Joseph A. Sparano, M.D., associate director for clinical research at the Albert Einstein Cancer Center and Montefiore Health System in New York City and vice chair of the ECOG-ACRIN Cancer Research Group. "With this new analysis, it is clear that women ages 50 or younger with a Recurrence Score result between 16 and 20 and at low risk clinically, do not need chemotherapy. Furthermore, the integration of the Recurrence Score with clinical risk information could identify premenopausal women with higher clinical risk who may benefit from ovarian function suppression and more aggressive anti-estrogen therapy."

The objective of the pre-specified secondary analysis was to evaluate whether clinical risk provides additional prognostic or predictive information to the RS results. Of 9,427 women in TAILORx with a RS and clinical risk information, 70 percent were determined to be low clinical risk (LCR: tumor  $\leq 3$  cm and low grade,  $< 2$  cm and intermediate grade, or  $\leq 1$  cm and high grade) and 30 percent were identified as high clinical risk (HCR: not meeting low clinical risk criteria). While clinical risk provided additional prognostic information across all RS groups, disease free survival and distant recurrence free interval rates were similar with and without chemotherapy in the entire RS 11-25 group irrespective of clinical risk. For the overall population, clinical risk alone was not predictive of chemotherapy benefit. This was also true for the two-thirds of women who were over the age of 50. For the remaining women aged 50 or younger, there was trend favoring chemotherapy irrespective of clinical risk, though not significant. This finding is consistent with the treatment interaction originally reported, between age/menopausal status, RS, and chemotherapy benefit.

Researchers studied the association between age at diagnosis and chemotherapy benefit in the group of younger women (age 50 or less) in TAILORx with a RS of 16-25. This group was of particular interest because they were part (14 percent) of the 30 percent of women in the original TAILORx findings for whom it was suggested that chemotherapy may be considered. Researchers sought to determine whether integration of RS and clinical information would help define this group. They found there was no benefit from chemotherapy for younger women (age 50 or less) with a RS of 16-20 and at low risk, clinically.

Researchers then explored the association between age at diagnosis and chemotherapy benefit in this group, to determine if integration of RS and clinical risk could help identify premenopausal women who might stand to benefit from more effective anti-estrogen therapy. In the original TAILORx report, researchers noted that it was unclear if the modest chemotherapy benefit seen in this group was due to a cytotoxic effect in eradicating micrometastatic disease, a castration effect in inducing early menopause, or both. Integration of RS and clinical risk found a benefit for women aged 46-50 years who were premenopausal but not postmenopausal, and a trend toward chemotherapy in women aged 41-45 years, but no benefit in women aged 40 years or under who are less likely to develop premature menopause from chemotherapy. In addition, there was no consistent effect favoring chemotherapy in older women. Taken together, these findings suggest that the chemotherapy benefit observed for the RS 16-25 group may be due to a castration effect associated with cytotoxic therapy.

Based on evidence from several prior studies, the 21-gene expression assay (Oncotype DX Breast Recurrence Score®) is widely used to provide prognostic information about the risk of breast cancer recurrence within 10 years, and to predict which patients are most likely to derive a large benefit from chemotherapy. The test is performed on a tumor biopsy sample. Women with a low score (0-10) typically receive only hormone therapy and those with a high score (26-100) receive hormone therapy and chemotherapy.

## ASCO2019 特集

### [News 01]

閉経前進行乳がんにおける生存率の改善

### [News 02]

新たに診断された進行胃がんに対する有望な代替手段

### [News 03]

レナリドミドは多発性骨髄腫の発症を遅延させる

### [News 04]

小児プレジジョン・メディシンの試験は予測を超える

### [News 05]

転移性前立腺がんの新たな治療選択

### [News 06]

肝転移において低侵襲がん手術は有効である

### [News 07]

ベムプロリズマブは非小細胞肺癌患者の生存率を上昇させる

### [News 08]

オラパリブはBRCA変異を有する膵臓がんの増悪を遅延させる

### [News 09]

新たな治療法は進行尿路上皮がんに対し有効である

### [News 10]

新しいクラスの薬剤は進行前立腺がん患者において有効である

### [News 11]

新たなデータは若年乳がん患者における術後補助療法のガイドとなる

### [News 12]

ビタミンDはがん関連死を減少させる

### [News 13]

リンパ腫の特定の亜型を有する患者は化学療法を回避することができる可能性がある

### [News 14]

乳房部分照射によりQOLが向上する

### [News 15]

チェックポイント阻害薬は肺がん再発を減少させるのに有望である

### [News 16]

HIV患者に対する免疫療法薬は安全であることが示された